Back to Journals » OncoTargets and Therapy » Call For Papers
OncoTargets and Therapy
The following Article Collection/ Thematic Series is currently open for submissions:
Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Radiation Therapies for Cancer" in OncoTargets and Therapy.
Radiation therapy remains a cornerstone in the treatment of various cancers. With continuous advancements in technology and a deeper understanding of cancer biology, radiation therapies are becoming more precise and effective. This Article Collection seeks to explore these advancements, including novel radiation techniques, toxicity management, and integration of radiation therapies with other treatment modalities.
We invite papers on topics including but not limited to:
- Innovative radiation techniques, including proton therapy, carbon ion therapy, and stereotactic body radiotherapy (SBRT).
- Technological innovations in radiation oncology, including the development and implementation of technologies such as artificial intelligence, machine learning, and image-guided radiation therapy (IGRT) in clinical practice.
- Radiation therapy and immunotherapy combinations.
- Personalized radiation therapy
- Radiation-induced toxicity management
The deadline for submissions is 1 December 2025. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.
Please submit your manuscript on our website, quoting the promo code MMCTR for a 10% discount on the Article Processing Charge and to indicate that your submission is for consideration in this Article Collection.
Call For Papers
Editor-in-Chief: Professor Gaetano Romano
To see where OncoTargets and Therapy is indexed online view the Journal Metrics.
What is the advantage to you of publishing in OncoTargets and Therapy?
- It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
- Although OncoTargets and Therapy receives a large number of papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
- The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. OncoTargets and Therapy has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
- Many authors have found that our peer reviewer’s comments substantially add to their final papers.
To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.
PubMed Central
OncoTargets and Therapy is indexed on PubMed Central (title abbreviation: Onco Targets Ther). All published papers in this journal are submitted to PubMed for indexing straight away.
Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.
Yours sincerely
Professor Gaetano Romano
Editor-in-Chief
OncoTargets and Therapy
Email: Editor-in-Chief
Updated 11 October 2022